Track Categories

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

Dementia is a decline in mental ability severe enough to interfere with day to day life. The most commonly occurring symptoms of dementia are decrease in ability to think and remember, emotional problems, problems with language, decrease in motivation. World Health Organisation’s list of top ten leading causes of deaths all over the world, Alzheimer’s and other dementias has 7th ranking. Dementia has overtaken as leading cause of death in England and Wales over heart diseases. Alzheimer’s disease is 6th leading cause of death in the USA and it kills more than breast and prostate cancer combined. To solve problems of globally various dementia conferences were arranged to find cure for dementia society universally..

  • Track 1-1Neurocognitive Disorder
  • Track 1-2Types of dementia
  • Track 1-3Prevalence of Dementia In UK
  • Track 1-4Current Researches on Dementia
  • Track 1-5Need for awareness on dementia

Alzheimer’s is most common type of dementia. Alzheimer’s is a chronic neurodegenerative disorder. Patient of Alzheimer’s shows early symptoms of short term memory and later progresses to problems in language, disorientation. Causes of Alzheimer’s are not clear yet, but 70% of risks are associated with genetics. There are no existing treatments to reverse or stop Alzheimer’s. Most of patients with Alzheimer’s are above 65 years of age but 4-5% cases are of early onset Alzheimer’s. It’s still one of the costly diseases. Alzheimer’s disease has been key topics in neurology conferences and dementia conferences. Separate Alzheimer’s conferences has been arranged to make aware world for its consequences. In 2016, hundreds of conferences has main topic as Alzheimer’s disease as it contributes to 60-70% cases of dementia. Several countries governments are taking initiative in Alzheimer’s congress such as UK, USA, Canada, France having high ratio of deaths due to Alzheimer’s patients and other dementias.

  • Track 2-1Alzheimer's Disease pathophysiology and mechanisms
  • Track 2-2Genetics in Alzheimer's Disease
  • Track 2-3Risk factors: head injury, depression and hypertention
  • Track 2-4Causes and preventions in Alzheimer's Disease
  • Track 2-5Medication and diet for Alzheimer's Disease
  • Track 2-6Symptoms of Alzheimer's Disease
  • Track 2-7Brain imaging for Alzheimer's Disease
  • Track 2-8Treatments for Alzheimer's Disease
  • Track 2-9Cholinergic and amloid hypothesis in Alzheimer's
  • Track 2-10Alzheimer's Disease associated complexities
  • Track 2-11Clinical Trials for Alzheimer's Disease
  • Track 2-12Recent advancements in Alzheimer's Disease
  • Track 2-13Latest tests for detection of Alzheimer's Disease

Vascular dementia is second most common type of dementia after Alzheimer’s. Reduced blood supply to brain which causes problems in supply of oxygen and nutrients to brain, causes series of minor attacks. Vascular dementia can’t be detected till it has series of attacks. Death of brain cells causes problems in memory, thinking and reasoning. There are various types of vascular dementiasuch as Stroke-related dementia, Post-stroke dementia, Single-infarct and multi-infarct dementia, subcortical dementia. High blood pressure, high blood cholesterol level, diabetes are some factors which help in prevention of vascular dementia. Vascular dementia is common type of dementia after Alzheimer’s disease contributing to nearly 20% cases making it significant in discussions of dementia congress.

  • Track 3-1Vascular dementia treatment and management
  • Track 3-2Vascular dementia prevalence
  • Track 3-3Pathology of vascular dementia
  • Track 3-4Risk factors in vascular dementia
  • Track 3-5Strokes in vascular dementia
  • Track 3-6Subcortical vascular dementia
  • Track 3-7Strategies for vascular dementia caregivers
  • Track 3-8Emerging therapies for vascular dementia

Alpha synuclein protein depositions in neurons cause Lewy body dementia. Symptoms of Lewy body dementia are hallucinations, rigidness in movement. In Lewy body dementia, disruption among brain cells occur, after one year of observation and progression in symptoms with Parkinson’s disease the diagnosis of Lewy body dementia is possible. If cognitive problems occur with a year of movement problems doctors declares it as Lewy body dementia and if not then it is declared as Parkinson’s disease. There are not specific stages as Lewy body dementia is progressive but early stage and late stage symptoms are found in literature. Lewy body dementia is common in men and in all races it’s equally found. It is normal kind of dementia after Alzheimer's illness and having same cases as vascular dementia making it critical in dialogs of dementia meetings.

  • Track 4-1Stages of Lewy body dementia
  • Track 4-2Alpha- synuclein protein associated with Lewy body dementia
  • Track 4-3Lewy body dementia and Parkinson' disease
  • Track 4-4Physiotherapy affects in Lewy body dementia
  • Track 4-5Advancement in treatment of Lewy body dementia
  • Track 4-6Latest Lewy body dementia research

Frontotemporal dementia is broad term for group of disorders caused by progressive nerve cell loss in the frontal and temporal lobes of brain. Spindle neurons have 70% loss in Frontotemporal dementia patients while other neurons remain unchanged. Temporal lobes have specific function such as right temporal lobe involved in recognition of faces and known objects. Left temporal lobe involved in meaning of names and words of objects. Frontotemporal dementia includes changes in behaviour, personality and difficulty in speech. It is significant cause of dementia in younger peoples. MRI scans may show the frontal and temporal lobe atrophy.

  • Track 5-1Frontotemporal dementia signs and diagnosis
  • Track 5-2Management of frontotemporal dementia
  • Track 5-3Spindle neurons
  • Track 5-4Primary progressive aphasia
  • Track 5-5Semantic dementia
  • Track 5-6Neuropsychological tests for frontotemporal dementia
  • Track 5-7Frontotemporal dementia and life expectancy

Mixed dementia is the coexistence of multiple dementias simultaneously. Alzheimer’s and Vascular dementia coexistence is most dangerous type of dementia. In some cases it will be really challenging to diagnose it as most of symptoms with resemble to Alzheimer’s and in different cases sign of mixed dementia will be there clearly. 94% of mixed dementia patients were first diagnosed with Alzheimer’s disease. Mixed dementia symptoms fluctuate with the areas of brain get affected. Currently there is no specific drug for mixed dementia but mostly physicians prescribe on the basis of patient conditions and normally the Alzheimer’s medicine is given to patients. Mixed dementia has been tricky topics of discussions in dementia meetings and dementia conferences since there is no legitimate technique to diagnose and no particular signs are there.

  • Track 6-1Medication in mixed dementia
  • Track 6-2Treatments for mixed dementia
  • Track 6-3Management of mixed dementia
  • Track 6-4Alzheimer's, Vascular and Lewy body dementia coexistence
  • Track 6-5Sleep and mixed dementia
  • Track 6-6Current research on Mixed Dementia

The Term “Stages of dementia” describes about how someone gets affected by dementia over the years. Although each stage is different discussing about this topic helps caregivers to understand the patient’s situation and plan how to care. They are classified into three stages classification: early stage dementia, mid-stage dementia and late-stage dementia. In The first stage of dementia the signs and symptoms are found to be faint. Mild cognitive impairment (MCI) is the earliest stage. The symptoms of early stages vary a lot based on the type of dementia. In case of mid stage the changes in the persons with dementia are obvious to people close to them, though outsiders may not notice them. Daily life and relationships are affected. They need more help because they are either unable to do tasks or have lost interest in everything. Frustration, anger, mood swings, and conflicts are common in mid stage dementia. In the late stage the patient is affected in all facet of life. They always become dependent for all activities. Their health gets worse in, multiple ways. The dementia conference also enlightens the people about stages of dementia.

  • Track 7-1Early stage dementia
  • Track 7-2Mid stage dementia
  • Track 7-3Late stage dementia
  • Track 7-4Mild cognitive impairement
  • Track 7-5Cognitive memory loss
  • Track 7-6Speech Impairment
  • Track 7-7Loss of Physcomotor skills

Dementia caused by various conditions can be reversed with appropriate treatment. The “reversible dementia” is the disorders found with cognitive or behavioral symptoms. These symptoms are not enough to fulfill the clinical criteria for dementia.The causes of potentially reversible dementia are drugs or alcohol abuse, space- occupying lesions, adverse effect of drugs, normal pressure hydrocephalus and metabolic conditions results in endocrinal conditions like hypothyroidism and nutritional condition like B-12 deficiency. Depression is the most common cause for reversible dementia. The potentially reversible dementias should be identified and considered for treatment.

  • Track 8-1Characteristics of reversible dementia
  • Track 8-2 Causes of reversible dementia
  • Track 8-3Depression
  • Track 8-4Adverse effect of drugs
  • Track 8-5Normal pressure hydrocephalus
  • Track 8-6Central nervous system infections
  • Track 8-7Alcohol abuse

The complete detailed assessment of dementia in needed to exclude similar symptoms showing to such diseases such as depression which is curable. It’s necessary to provide time to dementia patients to plan future and make them literate about the possible affects in future. There are various tests for diagnosing dementia such as Mini Mental State Examination (MMSE), Mental Score test, Trail making test. MMSE test include series of exercises in which various problems are checked with memory, speech, ability to respond. Blood test is also done to check levels of vitamin B12 and thyroid hormones which may be responsible. Brain scans such as MRI and CT scans used for checking brain tumour and strokes in vascular dementia. Neurology gatherings talked about rigorously on dementia diagnosis as its mistaking for different maladies like Parkinson’s' disease in which they discover in which they establish new methodologies and techniques for analysis as dementia society is in dire need of dependable diagnosis methods.

  • Track 9-1Measuring proteins in blood
  • Track 9-2Mini mental state examination
  • Track 9-3Mental score test
  • Track 9-4Trail making test
  • Track 9-5Clock drawing test
  • Track 9-6Geriatric depression scale
  • Track 9-7Brain MRI scan
  • Track 9-8People with memory problems
  • Track 9-9Biomarkers for diagnosis

Causes of dementia depend on areas of brain affected due to dementia. Dementia is progressive in nature; one of most common type of progressive dementia is Lewy body dementia. There are four primary form of reversible dementia: hypothyroidism, vitamin B12 lack, neurosyphillis and Lyme disease. Head injury, stroke or brain tumour may cause dementia. Age is one of the most important risk factor of dementia, 65years exceeding persons has more chances of having dementia. Ageing and genetic inheritance from ancestors is beyond control but other risk factors such as hypertension, hyperlipidaemia, hyperthoiroidism, alcohol use in large amounts, smoking can be prevented or controlled. Few risk factors can be prevented with healthy lifestyle and proper diet. Causes and risk elements have contributed enormously in dementia research and discovered new measures in dementia conferences.

  • Track 10-1Age: factor for dementia related diseases
  • Track 10-2Mental illness
  • Track 10-3Hypertension
  • Track 10-4Genetics in Dementia
  • Track 10-5Hypothryroidism
  • Track 10-6Vitamin B12 deficiency
  • Track 10-7Neurosyphillis
  • Track 10-8Beta Amloid Accumulation
  • Track 10-9Perception and visual problems
  • Track 10-10Traumatic brain injury
  • Track 10-11Down syndrome
  • Track 10-12Mild cognitive impairment

Dementia patients need assistance and full time care as much as drugs. Some common care practices in dementia are assistance in food and fluid consumption, pain management, social engagement ensuring safety and security of dementia patients. Main aim of care practices is to ensure cut in hospitalisation and psychotropic drugs. Understanding patient’s mood changes, particular behaviour, speech problems and help in rectifying them. Dementia patients need end of life care so qualified nursing staff is needed. Few care practices which are used are indoor and outdoor activities, visual and audio stimulation, art therapy. Care practices in dementia have been critical to partake in international dementia meetings. In need to evolve in dementia care world gathering and genuine talks on dementia care is required.

  • Track 11-1End of life care
  • Track 11-2Ensuring safety and security of dementia patients
  • Track 11-3Exercise promoting mobility and special diet for dementia patients
  • Track 11-4Visial and acoustic stimulation
  • Track 11-5Communication affects over dementia patients
  • Track 11-6Emergency preparedness
  • Track 11-7Social engagement
  • Track 11-8Art therapy- quality of life
  • Track 11-9Telecare

Dementia is advancing and incapacitating disease that affects more number of people around the world. Diagnosis of the patient with dementia makes a frightening scenario for those affected by syndrome, their family members and caretakers. Insufficient knowledge of its symptoms and supports available, conceive us to see inefficient and ineffective approach to provide services to the people with dementia. Better understanding about public awareness of dementia aids more effective health and social policies. The dementia conference discusses Public awareness to achieve higher rate of early diagnosis and to decrease the distress among the patient, family and caregiver.

  • Track 12-1Public awarness
  • Track 12-2Social policy
  • Track 12-3National and local awareness activities
  • Track 12-4Health and social system developments
  • Track 12-5Support for informal care and caregivers

Case reports in dementia supports the comprehensive report of causes, symptoms, treatment and possible outcome. Each case report distinguishes in conditions such as age, family background, treatment given and effects of it. This all helps to design, categorise the future aspects of disease. Case report will be highly helpful for the researchers to develop new methods and for physicians to develop diagnosis of dementia patients. Case reports in dementia gives some thought regarding diagnosis, treatment and level of cure perhaps conceivable preventions to be taken moreover. Be that as it may, most recognized case reports have been talked about in past dementia conferences have been extremely useful to researchers to carry on with their work.

  • Track 13-1Person living with dementia
  • Track 13-2History of present illness in dementia patients
  • Track 13-3Coping with caring
  • Track 13-4HIV associated dementia case report
  • Track 13-5Vocalisation in dementia
  • Track 13-6Nonconvulsive seizures and dementia

Rigorous clinical trials on dementia drugs are continuing in USA and UK. The most of drugs are in II and III phases. The most problems pharmaceutical companies facing are inadequate participants for trials. Most of clinical trials are done in specific areas are Amyloid beta plaques, the immune system, Tau tangles. Dementia conferences exhibit clinical trial medications and offers positivity to new prospects in curing dementia.

  • Track 14-1Vaccine against beta-amloid
  • Track 14-2Beta-amloid polymerisation and inflammation inhibitor
  • Track 14-3Aggregation of Tau inhibition
  • Track 14-4Prevention trials
  • Track 14-5Advances in genetic research

The existing drugs such as Cholinesterase inhibitors and Memantine are usually used to treat dementia and some other antidepressant also used with the treatments. Drugs are prescribed on the basis of severity of symptoms, such as mild-moderate dementia and moderate-severe dementia. New medications for dementia being developed in 2014/2015, 31% were named symptoms modifying. There are many developments are going on in drug discovery of dementia as old treatments are unable to stop the progression of dementia. Most associations share their exploration on new medications for dementia in dementia conferences to get higher esteem to their items. This gets to be distinctly gainful to different geriatric doctors to redesign themselves with such medications and progressing possibilities by going to dementia conferences. Such dementia meetings will help researchers to know target areas for drug development in dementia and work toward it.

  • Track 15-1Cholinesterase inhibitors
  • Track 15-2Memantine
  • Track 15-3Medication for memory loss
  • Track 15-4Beta and gamma secretase inhibitors
  • Track 15-5Vitamin E and Omega-3-fatty acids
  • Track 15-6New drug development in dementia

To treat dementia it needs new drug compounds and animal models for guaranteeing safety and effectiveness of drugs. Major cause of dementia is genetics, dementia occur due to genetic factors for such dementias transgenic and gene targeted models are used. Animal models contribute as model organism similar to human i.e. homologous models showing exceptional results that matches conditions in dementia patients. The most commonly used animal models are transgenic mice model, zebra fish model, Drosophila melanogaster model. Drosophila melanogaster models are used in neuroimaging techniques. All these models immensely help in new research and discoveries of dementia related methods and drugs. A few global dementia conference arguments have indicated animal model’s significance in diagnosing pharmacological impacts.

  • Track 16-1Transgenic mice model
  • Track 16-2Rodent models
  • Track 16-3Transgenic and gene targeted models in dementia
  • Track 16-4Pharmacological validation in animal model of dementia
  • Track 16-5Validation of dementia models employing neuroimaging techniques
  • Track 16-6Drosophila melanogaster as a model organism for dementia
  • Track 16-7Zebrafish as a model organism for dementia
  • Track 16-8Lesion-induced vertebrate models of Alzheimer's Disease
  • Track 16-9APP-based transgenic models

Advancement in treatment in dementia is needed in understanding under laying causes of dementia. Reminiscence therapy has shown good effects on dementia patients. Dementia is one of the most costly disease in world, this therapy is easy to conduct and inexpensive. Reminiscence therapy uses past incidences and encourage patients to write and explain past incidences which helps in maintaining mental health. As depression can be one of most causes of dementia, psychotherapy helps such patients immensely. Dementia care through cloud technology helps patients in keeping track of their conditions and progress rate, supporting staff and planning in daily care in dementia. Advancement in such therapies using technology and natural therapies will help physicians to treat dementia effectively. New progressions have been subject of dementia meetings and prime wellspring of learning with respect to Dementia, these dementia gatherings has taken one stage nearer to dementia cure.

  • Track 17-1Reminiscence therapy
  • Track 17-2Psychological therapies
  • Track 17-3Dementia care advances through cloud technology
  • Track 17-4Natural treatments in dementia
  • Track 17-5Advances in person centred care in dementia
  • Track 17-6Home care therapies